-
TRI-CON 2026 Highlights Recent Advances and Evolving Challenges in Precision Medicine
Read time: 7 minutes. Lung cancer sits at the forefront of precision medicine, with a large number of targeted therapies approved to treat patients based primarily on driver -
Defining Clinical Meaningfulness and Evolving Trial Design Standards Highlighted at ODAC's April 2026 Meeting
Read time: 7 minutes. The US Food and Drug Administration (FDA) Oncologic Drug Advisory Committee (ODAC) convened on April 30, 2026, to evaluate two applications. In the morning -
Promoting Alignment for Patient Experience Data: LUNGevity Comments on European Medicines Agency Reflection Paper
Patient experience data (PED) are data providing information about patients’ experiences with a disease or condition, including experiences with disease symptoms, impacts, and -
Transforming Clinical Trials Initiative 2026 First Quarter Updates
As we celebrate our 10 th anniversary of The Transforming Clinical Trials Initiative (TCTI) in 2026, we look forward to continuing our mission to improve the efficiency and -
Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
On October 22, 2025, the US Food and Drug Administration (FDA) released a final guidance document on Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for -
Transforming Clinical Trials Initiative 2025 Fourth Quarter Updates
LUNGevity Foundation’s Transforming Clinical Trials Initiative (TCTI) develops collaborative strategies to enhance innovation and patient access to safe and effective lung cancer